机译:Bortezomib在多发性骨髓瘤患者中改善了终末期肾功能衰竭的结果
Max-Eder-Group 'Experimental Therapies for Hematologic Malignancies' Heidelberg University;
Department of Medicine v Heidelberg University Hospital INF 410Heidelberg Germany;
Department of Medicine v Heidelberg University Hospital INF 410Heidelberg Germany;
Division of Nephrology Heidelberg University HospitalHeidelberg Germany;
Department of Medical Oncology National Center for Tumor DiseasesHeidelberg Germany;
Department of Medicine v Heidelberg University Hospital INF 410Heidelberg Germany;
Department of Medicine v Heidelberg University Hospital INF 410Heidelberg Germany;
Department of Medicine v Heidelberg University Hospital INF 410Heidelberg Germany;
Division of Nephrology Heidelberg University HospitalHeidelberg Germany;
Department of Medical Oncology National Center for Tumor DiseasesHeidelberg Germany Department;
Max-Eder-Group 'Experimental Therapies for Hematologic Malignancies' Heidelberg University;
机译:硼替佐米可改善多发性骨髓瘤终末期肾衰竭患者SCT后的预后
机译:硼替佐米治疗多发性骨髓瘤和肾功能衰竭患者的肾功能快速改善
机译:ERA-EDTA注册研究对因多发性骨髓瘤或轻链沉积病导致的终末期肾脏疾病开始肾脏替代治疗的患者的发生率和结果:
机译:使用选定的临床结果,极热对美国东北部终末期肾脏疾病患者的影响
机译:Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物,最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
机译:剂量调整的来那度胺治疗糖尿病合并肾病终末期肾病并需血液透析的患者,通过剂量调整的来那度胺疗法成功治疗了具有不确定性的单克隆博美氏病所致的硼替佐米难治性多发性骨髓瘤
机译:错误:多种骨髓瘤相关的患者的长期结果,术后自动SCT之后